Here's Why You Should Add Cooper Companies Stock to Your Portfolio Now

• CooperVision achieved its 18th consecutive year of market share gains, with MiSight myopia-control revenues growing 24% to $32 million in Q2, led by strong adoption in Japan and Europe.
• CooperSurgical's fertility segment posted 10% organic revenue growth to $144 million, supported by IVF cycle increases and new clinic wins, providing a counterbalance to contact lens weakness in Asia-Pacific.
• Second-half margins face pressure from approximately $22 million in tariff costs, unfavorable FX impacts, and freight expenses, with Q3 gross margin expected to decline to around 66% despite strong first-half profitability.

Cooper Companies Investment Summary

Company Overview

The Cooper Companies (COO), a global specialty medical device manufacturer with a $14.98 billion market cap, operates through two main divisions: CooperVision (contact lenses) and CooperSurgical (women's health/fertility products).

Key Performance Metrics

• Stock Performance: COO gained 3.1% over three months, underperforming the Medical-Dental Supplies industry (+7.4%) and S&P 500 (+12.5%)
• Earnings Growth: Bottom line projected to improve 8.3% over five years; beat estimates in last four quarters with 5.80% average surprise
• Fiscal 2026 Outlook: Revenue consensus at $4.31 billion (+5.3% YoY); adjusted EPS at $4.63 (+12.4% YoY)

Growth Drivers

CooperVision: Achieved 18th consecutive year of market share gains driven by premium lens migration. MiSight myopia-control revenues rose 24% to $32 million in Q2, with strong adoption in Japan and Europe.

CooperSurgical: Q2 revenues increased 8% to $358 million; fertility revenues up 10% organically to $144 million, supported by IVF cycle growth and new clinic wins.

Headwinds

• Asia-Pacific Weakness: Regional revenues declined 6% in Q2 due to soft demand in Japan and China; headwinds expected through 2027
• Margin Pressure: Q3 gross margin forecast at ~66% due to unfavorable FX, tariffs (~$22 million impact), and freight costs
• Guidance: Full-year CooperVision organic growth lowered to 3.5-4.5%

Investment Outlook

Zacks ranks COO #2 (Buy), citing strong myopia-management franchise, fertility recovery, and premium product migration, though near-term execution risks and regional challenges warrant monitoring.